New Delhi: Aurobindo Pharma on Wednesday said it has received US health regulator’s nod to market ‘Galantamine Tablets´, used in the treatment of Alzheimer disease, in the American market.
The Hyderabad-based firm has received approval from US Food and Drug Administration to market and manufacture Galantamine Tablets in strengths of 4mg, 8mg and 12mg, Aurobindo Pharma said in a statement.
“The product has a market size of approximately $41 million for the twelve months ending September 2010, according to IMS and will be launched shortly,” the company said.
Galantamine Tablets is the generic version of Ortho McNeil Janssen Pharmaceutical Inc’s Razadyne Tablets and falls under the neurological (CNS) therapeutic category.
The tablets are used for treatment of mild to moderate dementia of the Alzheimer’s type.
Shares of Aurobindo Pharma on Wednesday closed at Rs193.80 on the Bombay Stock Exchange, up 1.17 from its previous close.